Similarities and Differences Between Multiple Sclerosis and Type 1 Diabetes

Overview

Journal Diabetes Metab Res Rev

Specialty Endocrinology

Date 2021 Oct 15

PMID 34651395

Citations 2

Authors

Valeria Pozzilli

Eleonora Agata Grasso

Valentina Tomassini

Affiliations

Soon will be listed here.

Abstract

Multiple sclerosis (MS) and type 1 diabetes (T1D) are chronic conditions that result from dysfunction of the immune system. Their common root in autoimmunity stimulates interest in the exploration of similarities and differences between the two diseases. Genetic susceptibility is relevant, creating a substrate, on which environmental factors act as a trigger of an aberrant immune response. Despite being both T-cell mediated disorders with a strong involvement of the humoral arm, immunomodulation is a mainstay of MS management, whereas hormone replacement therapy remains the principal approach for T1D. T1D is usually diagnosed in children and adolescents, while MS is typical of young adults. This difference has implications for disease progression and treatment. The SARS-CoV-2 pandemic and its effect on immunity may affect the prevalence of these conditions, as well as their clinical manifestation.

Citing Articles

Exploring proteomic immunoprofiles: common neurological and immunological pathways in multiple sclerosis and type 1 diabetes mellitus.

Cano-Cano F, Lara-Barea A, Cruz-Gomez A, Martin-Loro F, Gomez-Jaramillo L, Gonzalez-Montelongo M Mol Med. 2025; 31(1):36.

PMID: 39901093 PMC: 11789306. DOI: 10.1186/s10020-025-01084-x.

The Prevalence of Comorbidities Associated with Multiple Sclerosis in Saudi Arabia.

Alnajashi H, Wali A, Aqeeli A, Magboul A, Alfulayt M, Baasher A Ann Afr Med. 2024; 23(4):600-605.

PMID: 39138964 PMC: 11556490. DOI: 10.4103/aam.aam_49_24.

Type 1 Diabetes Mellitus and Multiple Sclerosis: An Association to Consider.

Almeida C, Venade G, Duarte D, Vaz A, Nascimento E Cureus. 2022; 14(10):e30762.

PMID: 36447698 PMC: 9701081. DOI: 10.7759/cureus.30762.

References

Filippi M, Bar-Or A, Piehl F, Preziosa P, Solari A, Vukusic S . Multiple sclerosis. Nat Rev Dis Primers. 2018; 4(1):43. DOI: 10.1038/s41572-018-0041-4. View

Tomassini V, Johansen-Berg H, Leonardi L, Paixao L, Jbabdi S, Palace J . Preservation of motor skill learning in patients with multiple sclerosis. Mult Scler. 2010; 17(1):103-15. PMC: 3671324. DOI: 10.1177/1352458510381257. View

Salter A, Fox R, Newsome S, Halper J, Li D, Kanellis P . Outcomes and Risk Factors Associated With SARS-CoV-2 Infection in a North American Registry of Patients With Multiple Sclerosis. JAMA Neurol. 2021; 78(6):699-708. PMC: 7980147. DOI: 10.1001/jamaneurol.2021.0688. View

Macaron G, Feng J, Moodley M, Rensel M . Newer Treatment Approaches in Pediatric-Onset Multiple Sclerosis. Curr Treat Options Neurol. 2019; 21(10):50. DOI: 10.1007/s11940-019-0592-z. View

Gough S, Simmonds M . The HLA Region and Autoimmune Disease: Associations and Mechanisms of Action. Curr Genomics. 2009; 8(7):453-65. PMC: 2647156. DOI: 10.2174/138920207783591690. View

. The expanding genetic overlap between multiple sclerosis and type I diabetes. Genes Immun. 2008; 10(1):11-4. PMC: 2718424. DOI: 10.1038/gene.2008.83. View

Leete P, Mallone R, Richardson S, Sosenko J, Redondo M, Evans-Molina C . The Effect of Age on the Progression and Severity of Type 1 Diabetes: Potential Effects on Disease Mechanisms. Curr Diab Rep. 2018; 18(11):115. PMC: 10043737. DOI: 10.1007/s11892-018-1083-4. View

Mulero P, Midaglia L, Montalban X . Ocrelizumab: a new milestone in multiple sclerosis therapy. Ther Adv Neurol Disord. 2018; 11:1756286418773025. PMC: 5952271. DOI: 10.1177/1756286418773025. View

Richardson S, Morgan N . Enteroviral infections in the pathogenesis of type 1 diabetes: new insights for therapeutic intervention. Curr Opin Pharmacol. 2018; 43:11-19. PMC: 6294842. DOI: 10.1016/j.coph.2018.07.006. View

10.

Maahs D, West N, Lawrence J, Mayer-Davis E . Epidemiology of type 1 diabetes. Endocrinol Metab Clin North Am. 2010; 39(3):481-97. PMC: 2925303. DOI: 10.1016/j.ecl.2010.05.011. View

11.

Lahaye C, Soubrier M, Mulliez A, Bardin T, Cantagrel A, Combe B . Effectiveness and safety of abatacept in elderly patients with rheumatoid arthritis enrolled in the French Society of Rheumatology's ORA registry. Rheumatology (Oxford). 2016; 55(5):874-82. DOI: 10.1093/rheumatology/kev437. View

12.

Yu L, Zhao Z, Steck A . T1D Autoantibodies: room for improvement?. Curr Opin Endocrinol Diabetes Obes. 2017; 24(4):285-291. PMC: 5815324. DOI: 10.1097/MED.0000000000000348. View

13.

Tomassini V, Fanelli F, Prosperini L, Cerqua R, Cavalla P, Pozzilli C . Predicting the profile of increasing disability in multiple sclerosis. Mult Scler. 2018; 25(9):1306-1315. PMC: 6681428. DOI: 10.1177/1352458518790397. View

14.

Dobson R, Ramagopalan S, Davis A, Giovannoni G . Cerebrospinal fluid oligoclonal bands in multiple sclerosis and clinically isolated syndromes: a meta-analysis of prevalence, prognosis and effect of latitude. J Neurol Neurosurg Psychiatry. 2013; 84(8):909-14. DOI: 10.1136/jnnp-2012-304695. View

15.

Shah V, Wu M, Polsky S, Snell-Bergeon J, Sherr J, Cengiz E . Gender differences in diabetes self-care in adults with type 1 diabetes: Findings from the T1D Exchange clinic registry. J Diabetes Complications. 2018; 32(10):961-965. DOI: 10.1016/j.jdiacomp.2018.08.009. View

16.

Dorman J, Steenkiste A, Burke J, Songini M . Type 1 diabetes and multiple sclerosis: together at last. Diabetes Care. 2003; 26(11):3192-3. DOI: 10.2337/diacare.26.11.3192. View

17.

Hagopian W, Ferry Jr R, Sherry N, Carlin D, Bonvini E, Johnson S . Teplizumab preserves C-peptide in recent-onset type 1 diabetes: two-year results from the randomized, placebo-controlled Protégé trial. Diabetes. 2013; 62(11):3901-8. PMC: 3806608. DOI: 10.2337/db13-0236. View

18.

Guo W, Li M, Dong Y, Zhou H, Zhang Z, Tian C . Diabetes is a risk factor for the progression and prognosis of COVID-19. Diabetes Metab Res Rev. 2020; 36(7):e3319. PMC: 7228407. DOI: 10.1002/dmrr.3319. View

19.

Rachid O, Osman A, Abdi R, Haik Y . CTLA4-Ig (abatacept): a promising investigational drug for use in type 1 diabetes. Expert Opin Investig Drugs. 2020; 29(3):221-236. DOI: 10.1080/13543784.2020.1727885. View

20.

Fisher K, Cuascut F, Rivera V, Hutton G . Current Advances in Pediatric Onset Multiple Sclerosis. Biomedicines. 2020; 8(4). PMC: 7235875. DOI: 10.3390/biomedicines8040071. View